Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Wheeler

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Midwifery & Women'S Health|May 14, 2013
Development and pilot outcome data of a midlife women's health assessment clinic: a comprehensive and multidisciplinary approach to health careAngela Deneris, Catherine Wheeler, Shanna Salmon
Contemporary Clinical Trials|July 18, 2006
Improving the design of phase II trials of cytostatic anticancer agentsAndrew Stone, Catherine Wheeler, Alan Barge
Behavioral Neuroscience|December 17, 2003
Behavioral phenotype of the reeler mutant mouse: effects of RELN gene dosage and social isolationWalter L Salinger, Pamela Ladrow, Catherine Wheeler
Contemporary Clinical Trials|June 30, 2006
Optimizing randomized phase II trials assessing tumor progressionAndrew Stone, Catherine Wheeler, Kevin Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerKathy D Miller, Jose Manuel Trigo, Catherine Wheeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumorsLaurens V Beerepoot, Sandra A Radema, Els O Witteveen, et al.
Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126Jeffrey L Evelhoch, Patricia M LoRusso, Zhanquan He, et al.
Cancer|January 3, 2025
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancersDevalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Midwifery & Women'S Health|May 14, 2013
Development and pilot outcome data of a midlife women's health assessment clinic: a comprehensive and multidisciplinary approach to health careAngela Deneris, Catherine Wheeler, Shanna Salmon
Contemporary Clinical Trials|July 18, 2006
Improving the design of phase II trials of cytostatic anticancer agentsAndrew Stone, Catherine Wheeler, Alan Barge
Behavioral Neuroscience|December 17, 2003
Behavioral phenotype of the reeler mutant mouse: effects of RELN gene dosage and social isolationWalter L Salinger, Pamela Ladrow, Catherine Wheeler
Contemporary Clinical Trials|June 30, 2006
Optimizing randomized phase II trials assessing tumor progressionAndrew Stone, Catherine Wheeler, Kevin Carroll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancerKathy D Miller, Jose Manuel Trigo, Catherine Wheeler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2006
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumorsLaurens V Beerepoot, Sandra A Radema, Els O Witteveen, et al.
Investigational New Drugs|January 26, 2008
Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumorsPatricia M LoRusso, Shirish M Gadgeel, Antoinette Wozniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 6, 2017
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple MyelomaDan T Vogl, Noopur Raje, Sundar Jagannath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2004
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126Jeffrey L Evelhoch, Patricia M LoRusso, Zhanquan He, et al.
Cancer|January 3, 2025
A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancersDevalingam Mahalingam, Taofeek K Owonikoko, Ebrahim Delpassand, et al.
Pageof 2